Gordie Howe Bridge to Open July 27 After U.S.-Canada Reach Toll Revenue Agreement 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Japan Wholesale Inflation Jumps as Energy Shock Drives Import Costs Higher 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
US Launches New Iran Strikes as Strait of Hormuz Conflict Escalates, Oil Prices Rise 
Gold Prices Set for Weekly Loss as Iran Tensions and Fed Rate Outlook Weigh 
US Back-to-School Spending Seen Falling as Families Focus on Essentials 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Dollar Slips After Fed Minutes as Iran Tensions, Inflation Risks Keep Markets Cautious 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Dollar Slips as Oil Prices Ease, Fed Rate Outlook Remains Uncertain 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Gold Price Rebounds as U.S.-Iran Tensions and Fed Minutes Keep Markets on Edge 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
